Berlex Laboratories, Inc.

Gilead Sciences, Inc.

Lifetime Products, Inc.

Schering Aktiengesellschaft

Pharmacopeia Drug Discovery, Inc.

Other

Bayer Intellectual Property Gmbh

Pharmacopeia Inc.

Gilead Calistoga LLC

Berlax Laboratories, Inc.

Bausch & Lomb Incorporated

Gary Bruce Phillips

David D Davey

Michael M Morrissey

Musong Kim

Bin Ye

Wei Xu

Shung C Wu

Damian O Arnaiz

Zuchun Zhao

William John Watkins

Brad Owen Buckman

Joshua J Van Veldhuizen

Gayatri Balan

Howard P Ng

William J Guilford

John J Baldwin

Roland Ellwood Dolle

Jennifer Anne Treiberg

Shawn David Erickson

James J Devlin

Vidyadhar Madhav Paradkar

Kirk L Stevens

Stephane Perreault

John V Parkinson

Michael H J Ohlmeyer

Gonghua Pan

Kirk McMillan

Leena Patel

Suet Chung Yeung

Jennifer Alissa Loyer-Drew

James G Taylor

Joshua A Kaplan

Jayaraman Chandrasekhar

John O Link

Thorsten A Kirschberg

Nathan E Wright

Julian Andrew Codelli

Neil H Squires

Wendell B Peery

Devan Naduthambi

Monica J Kochanny

Chien-Hung Chou

Jeff A Zablocki

Robert A Astle

Scott A Mitchell

Jeromy J Cottell

Rao V Kalla

Elizabeth M Bacon

Sheila M Zipfel

Scott D Schroeder

Thao Perry

Seung H Lee

Jerry B Evarts

Christopher T Clark

Mark J Bartlett

Jennifer R Lo

John H Conway

Carl R Stanford

Barton W Phillips

Jennifer Leigh Cosman

Yuo-Ling Chou

S Curtis Nye

Sundaramoorthi Swaminathan

Zhimin Du

Kenneth Jay Shaw

Roland D Saito

Marcin Stasiak

Danny Green

William Baker

Steven T Sakata

Zhenze Hu

Charles Monsen

Raju Mohan

William C Lumma, Jr

Shendong Yuan

Guo Ping Wei

Judi Bryant

David C Winter

Hyung-Jung Pyun

Hans Briem

Dirk Kosemund

Eda Y Canales

Brent Steed

Joachim Kuhnke

Stefan Jaroch

Petr Jansa

Meina Liang

Chienhung Chou

Adam James Schrier

Michael Sangi

Rich Howe

Martin Krueger

Richard L Feldman

Peter Esperling

Thomas K Morgan, Jr

Lars Wortmann

Marc Adler

Christoph Huwe

Stefan Baeurle

James Onuffer

The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

Substituted 6-azabenzimidazole compounds

In one example, a method includes positioning a tool in a mold, forming a parison of melted plastic, closing the mold around the parison and tool such that part of the tool is positioned between a portion of the mold and the parison, creating a blow molded structure by inflating the parison so that the melted plastic comes into contact with an interior portion of the mold and into contact with the tool, and after the mold is closed, operating the tool to form an integral compression molded element within the mold, and a parting line formed by the mold in the blow molded structure forms no part of the integral compression molded element.

Blow molded part including compression molded element

The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Inhibitors of peptidylarginine deiminases

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Cot modulators and methods of use thereof

In one example, a structure is provided that includes a plastic body having a unitary, single-piece construction. The plastic body further includes a substantially hollow interior, and a parting line that extends around a portion of the perimeter of the structure. The structure also includes a solid compression molded element that is integral with the plastic body. The solid compression molded element is configured and arranged such that the parting line is not connected to the solid compression molded element.

The improved thinning or clearcut head is configured a tree harvesting vehicle supported by a plurality of wheels and tires. The improved thinning or clearcut head is adapted for use in cutting down a target tree. The improved thinning or clearcut head comprises a tree harvesting vehicle and a lateral pivot apparatus. The tree harvesting vehicle comprises a harvest vehicle and a cutting tool. The lateral pivot apparatus attaches the cutting tool to the harvest vehicle such that the cutting tool rotates around a lateral axis of rotation that is parallel to the center axis of the target tree. The improved thinning or clearcut head aligns the cutting tool with the target tree such that the alignment axis between the clamping arms of the cutting tool and the target tree is offset from primary sense of direction of the harvest vehicle.

Thinning or clearcut head

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A', B&#x2032;, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

Phosphatidylinositol 3-kinase inhibitors

A foot assembly includes a block retainer and a non-skid block. The block retainer is configured to be positioned at least proximate to an edge between a bottom surface and a side surface of a structure. The block retainer includes a planar portion, an angled portion, and a front surface. The planar portion has an interior surface configured to contact the bottom surface. The angled portion is diposed at an angle from the planar portion and includes an interior surface configured to contact an angled contact surface of the structure. The front surface includes a first dynamic coefficient of friction (DCOF). The non-skid block is connected to the planar portion and includes an exterior portion extending from the front surface away from the structure and includes a second DCOF greater than the first DCOF.

Foot assemblies

Growing community of inventors

Pleasant Hill, CA, United States of America

Gary Bruce Phillips